The Bleeding with Antithrombotic Therapy Study 2

The Bleeding with Antithrombotic Therapy Study 2 - BAT2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023669

Enrollment

6000

Registered

2016-08-18

Start date

2016-10-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular and cardiovascular diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with cerebrovascular or cardiovascular diseases who start or continue taking oral antithrombotics (antiplatelets and/or anticoagulants) to prevent vascular events 2. Patients who are able to receive MRI 3. Provision of written informed consent either directly or by a suitable surrogate

Exclusion criteria

Exclusion criteria: 1. MRI contraindication 2. Any condition that in the opinion of the responsible physician or investigator that renders the patient unsuitable for the study

Design outcomes

Primary

Measure	Time frame
ISTH major bleeding	—

Secondary

Measure	Time frame
1. Clinically relevant non-major bleeding 2. Hemorrhagic event details 3. Ischemic events and those details	—

Countries

Japan

Contacts

Public ContactMasahito Takagi

National Cerebral and Cardiovascular Center Division of Cerebrovascular Medicine, Department of Stroke and Cerebrovascular Diseases

bat2@ncvc.go.jp06-6170-1070

Outcome results